^
    4years
    Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma. (PubMed, J Cell Mol Med)
    The use of two EPHB4 inhibitors, JI-101 and NVP-BHG712, was able to rescue the phenotype driven by the variant. Our study suggested that EPHB4 is a promising therapeutic target in high-risk NB.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • CDK4 (Cyclin-dependent kinase 4) • RAF1 (Raf-1 Proto-Oncogene Serine/Threonine Kinase) • EPHB4 (EPH receptor B4)
    |
    JI-101